Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).
Cyclopharm Limited has announced a change in the director’s interest, with John William Wigglesworth acquiring 13,500 ordinary shares through an on-market trade, increasing his total holdings to 67,479 shares. This acquisition may indicate confidence in the company’s future prospects and could impact investor perceptions positively, reflecting potential growth or strategic developments within the company.
More about Cyclopharm Limited
Cyclopharm Limited operates in the healthcare industry, focusing on the development and distribution of medical and pharmaceutical products. The company is known for its specialized imaging and diagnostic solutions, particularly in the field of nuclear medicine.
YTD Price Performance: 20.25%
Average Trading Volume: 110,041
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: A$211.2M
See more insights into CYC stock on TipRanks’ Stock Analysis page.